| | Family Health | Pediatrics
Juvenile Parkinsonism: Early-Onset Parkinson's in Children and Adolescents
Epidemiology
- Incidence: ~0.1-0.5 per 100,000 children/year (vs. ~150/100,000 in >60 years).
- Age Definitions: Juvenile (<21 years), Young-Onset (21-40), Late-Onset (>40).
- Genetic Proportion: >50% juvenile cases have identifiable mutations vs. ~10-15% adult-onset.
Genetic Etiologies
| Gene | Inheritance | Onset | Features |
|---|---|---|---|
| PRKN (PARK2) | Autosomal Recessive | Juvenile (mean 16) | Most common; slow progression; dystonia; good levodopa response; cognitive sparing |
| PINK1 (PARK6) | AR | Early adulthood | Similar to PRKN; mitochondrial quality control defect |
| DJ-1 (PARK7) | AR | Young | Rare; psychosis, cognitive features possible |
| SNCA (PARK1/4) | Autosomal Dominant | Young-adult | α-synuclein multiplication; rapid progression; dementia |
| LRRK2 (PARK8) | AD | Variable (can be juvenile) | Most common genetic PD overall; incomplete penetrance |
| VPS35, CHCHD2, DNAJC13 | AD | Adult/Young | Rare; vesicular trafficking, mitochondrial |
Clinical Presentation
- Classic triad: Bradykinesia + Rigidity + Rest Tremor (may be absent initially).
- Atypical Features in Juvenile: Dystonia (especially foot inversion), gait disturbance, cognitive/behavioral issues, psychiatric comorbidities.
- Non-Motor: Sleep disorders, autonomic dysfunction, sensory symptoms, mood disorders – often precede motor signs.
Diagnostic Workup
- Clinical: Detailed history, neurological exam (UPDRS), family pedigree.
- Genetic Testing: Panel (PRKN, PINK1, DJ-1, SNCA, LRRK2, VPS35) + CMA/WES if negative.
- Imaging: DaTscan (dopamine transporter SPECT) – confirms dopaminergic deficit; MRI (exclude structural).
- Levodopa Challenge: Dramatic response supports diagnosis.
Management
Pharmacologic
- Levodopa/Carbidopa: Gold standard; start low (50-100 mg/day); juvenile patients often highly sensitive → dyskinesias.
- Dopamine Agonists: Pramipexole, ropinirole, rotigotine – delay levodopa; impulse control risk.
- MAO-B Inhibitors: Rasagiline, selegiline – mild benefit, neuroprotective potential.
- Anticholinergics: Trihexyphenidyl – for tremor/dystonia; cognitive side effects limit use.
Advanced Therapies
- DBS (Deep Brain Stimulation): STN or GPi; considered for motor fluctuations/dyskinesias refractory to meds. Age not absolute barrier.
- Infusion Therapies: Duopa (levodopa/carbidopa intestinal gel), apomorphine pump.
Multidisciplinary Care
- Pediatric/adult movement disorder neurologist, PT/OT/SLT, neuropsychology, genetics, social work, education liaison.
- School accommodations (IEP/504): fatigue management, motor breaks, assistive tech.
Prognosis
- Generally slower progression than adult-onset; decades of functional independence common.
- Genotype influences trajectory (PRKN > LRRK2 > SNCA).
- Lifespan near-normal with modern management.
Juvenile parkinsonism is a distinct entity requiring genetic diagnosis, age-tailored treatment, and lifespan care planning. Early specialist referral optimizes outcomes.
Pediatrics - Related Articles
- Navigating Different Parenting Styles: 9 Strategies for Cohesion
- Understanding Pediatricians: Your Child's Health Experts
- Ultrasound (Sonogram): What It Is and How It Works
- DAN Protocol: Understanding Dietary Approaches for Autism
- Smartphones for Kids: Weighing the Pros and Cons
- Confidentiality in Childcare: Protecting Children's and Families' Privacy
- Cleft Lip & Palate Treatment: A Comprehensive Guide for Parents
